Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,408.00
Bid: 12,406.00
Ask: 12,410.00
Change: 62.00 (0.50%)
Spread: 4.00 (0.032%)
Open: 12,334.00
High: 12,416.00
Low: 12,322.00
Prev. Close: 12,346.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding - Replacement

8 May 2015 11:00

RNS Number : 6336M
AstraZeneca PLC
08 May 2015
 



GENERAL TEXT AMENDMENT

 

The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 8 May 2015 at 10.00am under RNS No 5525M.

 

The grant date of the award of shares has been corrected to September 2014 from September 2015.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 

On 7 May 2015, the interest of Luke Miels, a person discharging managerial responsibilities, in AstraZeneca PLC Ordinary Shares of $0.25 each changed as detailed below.

 

The change in interest relates to the vesting on 7 May 2015 of an award of shares granted in September 2014 under the AstraZeneca Restricted Share Plan. In accordance with the terms of the award, Mr Miels has become beneficially entitled to all of the shares originally awarded.

 

Sufficient vested shares have been withheld to cover certain tax obligations arising on the vesting and the net number of shares has been delivered into a personal brokerage account.

 

 

 

Plan

Shares awarded

Shares vested

Shares withheld

Net shares received

 

AstraZeneca Restricted Share Plan

 

7,776

 

7,776

 

2,791

 

4,985

 

 

For tax purposes, the fair market value of the shares at vest was 4413.5 pence per share being the closing price of AstraZeneca shares on the last trading day preceding the vesting day.

 

 

A C N Kemp

Company Secretary

8 May 2015

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSKVLBBEEFZBBK
Date   Source Headline
13th Jan 20207:01 amRNSLynparza granted FDA Priority Review for PAOLA-1
13th Jan 20207:00 amRNSUpdate on Epanova Phase III STRENGTH trial
6th Jan 20207:01 amRNSFarxiga granted FDA heart failure Priority Review
6th Jan 20207:00 amRNSLokelma approved in China for hyperkalaemia
2nd Jan 20203:00 pmRNSTotal Voting Rights
30th Dec 20197:00 amRNSUS FDA approved Lynparza for pancreatic cancer
23rd Dec 20197:00 amRNSTriple-combination approved in China for COPD
23rd Dec 20197:00 amRNSEnhertu (trastuzumab deruxtecan) approved in US
20th Dec 20197:00 amRNSAstraZeneca divests rights to Arimidex and Casodex
17th Dec 20196:06 pmRNSFDA panel backs Lynparza use for pancreatic cancer
16th Dec 20197:00 amRNSSeroquel rights agreement complete: Europe, Russia
12th Dec 20197:00 amRNSImfinzi approved in China for Stage III NSCLC
11th Dec 20191:00 pmRNSTrastuzumab deruxtecan achieves ORR of 60.9%
5th Dec 20197:00 amRNSLynparza approved in China for 1L BRCAm ovarian
3rd Dec 20197:00 amRNSAstraZeneca divests Seroquel rights: US and Canada
2nd Dec 20193:00 pmRNSBlock listing Interim Review
2nd Dec 20193:00 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSImfinzi granted FDA Priority Review for SCLC
21st Nov 20196:15 pmRNSCalquence approved in CLL in the US
15th Nov 20197:00 amRNSQtrilmet approved in the EU for treatment of T2D
14th Nov 20197:00 amRNSFDA accepts regulatory submission for selumetinib
12th Nov 20197:00 amRNSAnifrolumab demonstrated superiority in TULIP 2
11th Nov 20197:00 amRNSRoxadustat pooled analyses: no increased CV risk
8th Nov 20197:00 amRNSRoxadustat significantly increased haemoglobin
6th Nov 20192:10 pmRNSCalquence data to show improved progression-free
1st Nov 20193:00 pmRNSTotal Voting Rights
30th Oct 20197:00 amRNSAstraZeneca divests rights to Seroquel and
28th Oct 20193:31 pmRNSImfinzi and Imfinzi plus tremelimumab delayed
24th Oct 20197:00 amRNSAstraZeneca year-to-date and Q3 2019 results
21st Oct 20197:00 amRNSFarxiga approved in the US to reduce the risk of
17th Oct 20197:00 amRNSTrastuzumab deruxtecan granted FDA Priority Review
4th Oct 20193:04 pmRNSHolding(s) in Company
4th Oct 20193:00 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSFasenra approved in the US for self-administration
3rd Oct 20194:00 pmRNSDirector Declaration
1st Oct 20193:00 pmRNSTotal Voting Rights
1st Oct 20197:05 amRNSAstraZeneca divests rights for Losec to Cheplaphar
1st Oct 20197:00 amRNSUpdate on US regulatory review of PT010 in COPD
30th Sep 20193:30 pmRNSLynparza more than doubled the time without
30th Sep 20197:00 amRNSTagrisso is the only 1st-line treatment for EGFR-
30th Sep 20197:00 amRNSLynparza improved the time women lived without
23rd Sep 20197:00 amRNSQtrilmet recommended for approval in EU by CHMP
18th Sep 20197:00 amRNSAstraZeneca amends collaboration with Ironwood
9th Sep 20198:38 amRNSImfinzi is first immunotherapy to show both
4th Sep 20197:11 amRNSTagrisso approved in China as a 1st-line treatment
2nd Sep 20193:00 pmRNSTotal Voting Rights
2nd Sep 20197:05 amRNSBrilinta reduced the risk of cardiovascular events
2nd Sep 20197:00 amRNSDetailed results from Phase III DAPA-HF trial
29th Aug 20197:00 amRNSAnifrolumab Phase III trial meets primary endpoint
28th Aug 20197:05 amRNSFasenra granted US Orphan Drug Designation for

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.